FibroBiologics shares are trading higher after the company announced it completed the manufacturing of the first batch of its proprietary CYWC628 drug product.

Benzinga Newsdesk www.benzinga.com Positive 95.3%

Neg 0% Neu 0% Pos 95.3%

Comments

No comments yet. Be the first!